Two Food and Drug Administration decisions that came down late last week are raising eyebrows. The agency postponed until December a final decision on whether to withdraw Avastin's approval for breast cancer. And the FDA announced it was investigating whether the diabetes drug Actos elevates the rate of bladder cancer among chronic users.
Will populist anger at what President Obama calls "fat-cat" bankers turn the tide against the generally well-compensated venture capital, private equity and hedge fund industries? With Obama's economic advisers consisting chiefly of Wall Street insiders and free-market acolytes, don't bet on it.
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.